The trajectory of companies tied to Sildenafil's past presents a intricate investment landscape. While the initial surge generated substantial gains, generic copies have significantly eroded revenue. Investing in associated pharmaceutical firms now requires a discerning assessment of proprietary protection , evolving healthcare changes, and the pot